Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents

L. Hoffmann, M. Kohls, S. Arnolds, P. Achenbach, R. Bergholdt, E. Bonifacio, E. Bosi, M. Gündert, BK. Hoefelschweiger, S. Hummel, P. Jarosz-Chobot, O. Kordonouri, V. Lampasona, P. Narendran, L. Overbergh, F. Pociot, JF. Raposo, Z. Šumník, A....

. 2025 ; 15 (1) : e088522. [pub] 20250102

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010348

INTRODUCTION: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening. With the EDENT1FI Master Protocol, the project aims to harmonise and standardise screening for early-stage type 1 diabetes and care. METHODS AND ANALYSIS: Public health islet autoantibody screening is conducted in the Czech Republic, Denmark, Germany, Italy, Poland, Portugal, Sweden and the UK. Between November 2023 (start date) and October 2028 (planned end date), an estimated number of 200 000 children and adolescents aged 1-17 years are expected to be screened. Screening is performed in capillary blood, examining different islet autoantibodies (autoantibodies against insulin, glutamic acid decarboxylase-65, insulinoma-associated antigen-2 and/or zinc transporter-8). Positive screening results undergo confirmation through a second antibody method. A second (venous) blood sample is requested if at least two autoantibodies are detected, to confirm the autoantibody status. Children and adolescents with confirmed two or more autoantibodies are invited to metabolic staging (oral glucose tolerance test, haemoglobin A1c (HbA1c), random glucose, optionally continuous glucose monitoring); an educational programme and recommendations for monitoring are provided. The feasibility and acceptability of screening are evaluated by feedback questionnaires. Pseudonymised data is collated in the EDENT1FI Registry. Study outcomes include country-specific screening rates, prevalences of stage 1 and stage 2 type 1 diabetes, number in EDENT1FI Registry, proportion with DKA and symptoms at clinical diagnosis and median HbA1c. ETHICS AND DISSEMINATION: Following the EDENT1FI Master Protocol, site-specific protocols are developed and approved by local ethics committees (Technical University of Munich, Medical Faculty, Nr. 70/14; Medizinische Hochschule Hannover, Nr. 9588_BO_S_2021; Technische Universität Dresden, Nr. BO-EK-356082020; Center for Sundhed Region Hovedstaden, Nr. H-22053116; Swedish Ethical Review Authority, Nr. 2023-00312-01; National Health Service Health Research Authority and Health Care Research Wales, IRAS (Integrated Research Application System) project ID 309252; Italian National Institute of Health, National ethics committee for clinical trials of public research bodies (EPR) and other national public institutions, Prot. PRE BIO CE Nr. 0059835; Charles University in Prague, Ethics Committee for Multi-Centric Clinical Trials of the University Hopital Motol and 2nd Faculty of Medicine, Nr. 1271/23; Bioethics Committee at the Medical University of Warsaw, Nr. 21/2024 and KB/6/R/2024; Associação Protectora dos Diabéticos de Portugal, Nr. 211/2024). Results are disseminated through peer-reviewed journals and conference presentations and will be shared openly.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010348
003      
CZ-PrNML
005      
20250429135340.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2024-088522 $2 doi
035    __
$a (PubMed)39753267
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hoffmann, Luisa $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany $1 https://orcid.org/0009000259720662
245    10
$a EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents / $c L. Hoffmann, M. Kohls, S. Arnolds, P. Achenbach, R. Bergholdt, E. Bonifacio, E. Bosi, M. Gündert, BK. Hoefelschweiger, S. Hummel, P. Jarosz-Chobot, O. Kordonouri, V. Lampasona, P. Narendran, L. Overbergh, F. Pociot, JF. Raposo, Z. Šumník, A. Szypowska, J. Vercauteren, C. Winkler, C. Mathieu, AG. Ziegler, EDENT1FI consortium
520    9_
$a INTRODUCTION: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening. With the EDENT1FI Master Protocol, the project aims to harmonise and standardise screening for early-stage type 1 diabetes and care. METHODS AND ANALYSIS: Public health islet autoantibody screening is conducted in the Czech Republic, Denmark, Germany, Italy, Poland, Portugal, Sweden and the UK. Between November 2023 (start date) and October 2028 (planned end date), an estimated number of 200 000 children and adolescents aged 1-17 years are expected to be screened. Screening is performed in capillary blood, examining different islet autoantibodies (autoantibodies against insulin, glutamic acid decarboxylase-65, insulinoma-associated antigen-2 and/or zinc transporter-8). Positive screening results undergo confirmation through a second antibody method. A second (venous) blood sample is requested if at least two autoantibodies are detected, to confirm the autoantibody status. Children and adolescents with confirmed two or more autoantibodies are invited to metabolic staging (oral glucose tolerance test, haemoglobin A1c (HbA1c), random glucose, optionally continuous glucose monitoring); an educational programme and recommendations for monitoring are provided. The feasibility and acceptability of screening are evaluated by feedback questionnaires. Pseudonymised data is collated in the EDENT1FI Registry. Study outcomes include country-specific screening rates, prevalences of stage 1 and stage 2 type 1 diabetes, number in EDENT1FI Registry, proportion with DKA and symptoms at clinical diagnosis and median HbA1c. ETHICS AND DISSEMINATION: Following the EDENT1FI Master Protocol, site-specific protocols are developed and approved by local ethics committees (Technical University of Munich, Medical Faculty, Nr. 70/14; Medizinische Hochschule Hannover, Nr. 9588_BO_S_2021; Technische Universität Dresden, Nr. BO-EK-356082020; Center for Sundhed Region Hovedstaden, Nr. H-22053116; Swedish Ethical Review Authority, Nr. 2023-00312-01; National Health Service Health Research Authority and Health Care Research Wales, IRAS (Integrated Research Application System) project ID 309252; Italian National Institute of Health, National ethics committee for clinical trials of public research bodies (EPR) and other national public institutions, Prot. PRE BIO CE Nr. 0059835; Charles University in Prague, Ethics Committee for Multi-Centric Clinical Trials of the University Hopital Motol and 2nd Faculty of Medicine, Nr. 1271/23; Bioethics Committee at the Medical University of Warsaw, Nr. 21/2024 and KB/6/R/2024; Associação Protectora dos Diabéticos de Portugal, Nr. 211/2024). Results are disseminated through peer-reviewed journals and conference presentations and will be shared openly.
650    _2
$a lidé $7 D006801
650    12
$a diabetes mellitus 1. typu $x diagnóza $7 D003922
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    12
$a plošný screening $x metody $7 D008403
650    12
$a autoprotilátky $x krev $7 D001323
650    12
$a časná diagnóza $7 D042241
650    _2
$a kojenec $7 D007223
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kohls, Mirjam $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Arnolds, Stefanie $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Achenbach, Peter $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany $u Forschergruppe Diabetes at Klinikum Rechts der Isar, Technical University of Munich School of Medicine, Munich, Germany
700    1_
$a Bergholdt, Regine $u Novo Nordisk A/S, Soeborg, Denmark
700    1_
$a Bonifacio, Ezio $u Center for Regenerative Therapies Dresden, Faculty of Medicine, TU Dresden, Dresden, Germany
700    1_
$a Bosi, Emanuele $u Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000223712495
700    1_
$a Gündert, Melanie $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Hoefelschweiger, Bianca K $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Hummel, Sandra $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Jarosz-Chobot, Przemysława $u Department of Children's Diabetology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
700    1_
$a Kordonouri, Olga $u Kinderkrankenhaus auf der Bult, Hanover, Germany
700    1_
$a Lampasona, Vito $u Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Narendran, Parth $u University of Birmingham, Birmingham, UK
700    1_
$a Overbergh, Lut $u Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
700    1_
$a Pociot, Flemming $u Department of Clinical Research, Translational Type 1 Diabetes Research, Steno Diabetes Center Copenhagen, Herlev, Denmark
700    1_
$a Raposo, João Filipe $u NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal $u Education and Research Center (APDP-ERC), APDP-Diabetes Portugal, Lisbon, Portugal
700    1_
$a Šumník, Zdeněk $u Department of Pediatrics, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
700    1_
$a Szypowska, Agnieszka $u Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Vercauteren, Jurgen $u Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
700    1_
$a Winkler, Christiane $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
700    1_
$a Mathieu, Chantal $u Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium $u Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Ziegler, Anette-Gabriele $u Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany anettegabriele.ziegler@helmholtz-munich.de $u Forschergruppe Diabetes at Klinikum Rechts der Isar, Technical University of Munich School of Medicine, Munich, Germany
710    2_
$a EDENT1FI consortium
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 15, č. 1 (2025), s. e088522
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39753267 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135336 $b ABA008
999    __
$a ok $b bmc $g 2311606 $s 1247429
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 1 $d e088522 $e 20250102 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace